In vitro and in vivo characterization of the transdermal delivery of sertraline hydrochloride films

DARU, Journal of Pharmaceutical Sciences

Volumn 19, Issue 6, 2011, Pages 424-432

  Vijaya, R ^a   Ruckmani, K ^a  

^a ANNA UNIVERSITY   (India)

Author keywords

Antidepressant; Ethyl cellulose; Eudragit; Hydroxy propyl methyl cellulose; In vitro and in vivo skin permeation

Indexed keywords

ETHYL CELLULOSE; EUDRAGIT; EUDRAGIT RS; HYDROXYPROPYLMETHYLCELLULOSE; OLEIC ACID; PROPYLENE GLYCOL; SERTRALINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTENT; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOISTURE; MOUSE; NONHUMAN; PHYSICAL PARAMETERS; SKIN IRRITATION; SKIN PENETRATION; TENSILE STRENGTH; THICKNESS; TIME TO MAXIMUM PLASMA CONCENTRATION; WATER VAPOR TRANSMISSION RATE;

EID: 84857418917     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hollister LE. A Lange Medical Book: Basic and Clinical Pharmacology. Norwalk, Connecticut: Appleton & Lange, 1995:448-59.
2. Kilts CD. Potential New Drug Delivery Systems for Antidepressants: An overview. J Clin Psychiatry 2003; 64: 31-3.
3. Frampton JE, Plosker GL. Selegiline transdermal system: in the treatment of major depressive disorder: Profile report. CNS Drugs. 2007; 21:521-24.
4. Singh G, Ghosh B, Kaushalkumar D, Somsekhar V. Screening of venlafaxine hydrochloride for transdermal delivery: passive diffusion and iontophoresis. AAPS PharmSciTech. 2008; 9:791-7.
5. Mutalik S, Udupa N. Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J Pharm Sci. 2004; 93:1577-94.
6. Mamatha T, Venkateswara Rao J, Mukkanti K, Ramesh G. Development of matrix type transdermal patches of lercanidipine hydrochloride: physicochemical and in-vitro characterization. DARU. 2010; 18:9-16.
7. Vijaya R, Ruckmani K. Effect of Eudragit E100 Based Polymeric Film in the Transdermal Delivery of Sertraline Hydrochloride. Journal of Pharmacy Research. 2011; 4: 1102-1104.
8. Melero A, Garrigues TM, Almudever P, Villodre AM, Lehr CM, Schafer U. Nortriptyline hydrochloride skin absorption: Development of a transdermal patch. Eur J Pharm Biopharm. 2008; 69:588-96.
9. Tanwar YS, Chauhan CS, Sharma A. Development and evaluation of carvedilol transdermal patches. Acta Pharm. 2007; 57:151-9.
10. Kusum DV, Saisivam S, Maria GR, Deepti PU. Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. Drug Dev Ind Pharm. 2003; 29:495-503
11. Gannu R,Vishnu YV, Kishan V, Rao YM. Development of nitrendipine transdermal patches: in vitro and ex vivo characterization. Current Drug Delivery. 2007; 4:69-76.
12. Ashok CR, Ranjan P, Verma P. Design and development of hydroxyl propyl methycellulose (HPMC)-based polymeric films of methotrexate: physicochemical and pharmacokinetic evaluations. Yakugaku Zasshi. 2008; 128:1057-66.
13. Shah SS, Tojo K, Huang Y-C, Chien YW. Development and clinical evaluation of a verapamil transdermal delivery system. J Control Rel. 1992; 22:125-31.
14. Das MK, Bhattacharya A, Ghosal SK. Transdermal delivery of trazodone hydrochloride from acrylic films prepared from aqueous latex. Indian Journal of Pharmaceutical Sciences. 2006; 68:41-6.
15. Draize JH, Woodard MG Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Therapeutics. 1944; 82:377-90.
16. Wade A, Weller PJ. Hand book of pharmaceutical excipients. DC: American Pharmaceutical Publishing Assoc, Washington, 2000; 250-55 and 401-6.
17. Aqil M, Sultana Y, Ali A. Matrix-type transdermal drug delivery systems of metoprolol tartrate: in vitro characterization. Acta Pharm. 2003; 53:119-25.
18. Rao PR, Diwan PV. Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Drug Dev Ind Pharm. 1998; 24:327-36.